임상시험의 단계별 이해 및 실제
Understanding of Clinical Trials and Application to the Real Practice
0
조회
0
다운로드
2
인용
0
참고문헌
키워드
초록
Understanding of a clinical trial is essential in developing clinical guideline and adopting evidence based practice. In designing and executing clinical trials, following ethical requirements should be considered : social value, scientific validity, fair subject selection, informed consent, favorable risk-benefit ratio, institutional review board, and respect for human subjects. According to the stage of drug development, purpose of trials, accumulated scientific data, clinical trials for drug development are classified as phase 1, 2, 3, and 4. Phases of clinical trials can be overlapped and the judgment of entering into the next phase should be considered highly strategically. In reading, evaluating and interpreting clinical trial reports, various skills and challenges exist. Patient sample composition, trial duration, selection of endpoints, responders and non-responders, placebo effect, patient recruitment, and extrapolation to the real world are the examples of those challenges. Treatment success will come from the well balanced approach of evidence based decision making and consideration of specific single case.
Abstract
Understanding of a clinical trial is essential in developing clinical guideline and adopting evidence based practice. In designing and executing clinical trials, following ethical requirements should be considered : social value, scientific validity, fair subject selection, informed consent, favorable risk-benefit ratio, institutional review board, and respect for human subjects. According to the stage of drug development, purpose of trials, accumulated scientific data, clinical trials for drug development are classified as phase 1, 2, 3, and 4. Phases of clinical trials can be overlapped and the judgment of entering into the next phase should be considered highly strategically. In reading, evaluating and interpreting clinical trial reports, various skills and challenges exist. Patient sample composition, trial duration, selection of endpoints, responders and non-responders, placebo effect, patient recruitment, and extrapolation to the real world are the examples of those challenges. Treatment success will come from the well balanced approach of evidence based decision making and consideration of specific single case.
참고문헌 (22)
- International Conference on Harmonization, "Guideline for Good Clinical Practice E6 (R1)", ~ (1996)
- Emanuel EJ, "What makes clinical research ethical?", JAMA, 283, pp.2701~2711 (2000)
- Wilding IR, "Improved early clinical development through human microdosing studies", Drug Discov Today, 10, pp.890~894 (2005)
- Ng R, "Clinical Trials, In Drugs: From Discovery to Approval. 2nd ed", pp.176~207 (2009), Wiley-Backwell
- Marder SR, "The effects of risperidone on the five dimensions of schizophrenia derived by factor analysis: combined results of the North American trials", J Clin Psychiatry, 58, pp.538~546 (1997)
- Honer WG, "Conceptual and methodological issues in the design of clinical trials of antipsychotics for the treatment of schizophrenia", CNS Drugs, 21, pp.699~714 (2007)
- Leucht S, "Early-onset hypothesis of antipsychotic drug action: a hypothesis tested, confirmed and extended", Biol Psychiatry, 57, pp.1543~1549 (2005)
- Gunduz-Bruce H, "Duration of untreated psychosis and time to treatment response for delusions and hallucinations", Am J Psychiatry, 162, pp.1966~1969 (2005)
- Bullinger M, "Evaluating quality-of-life measures for clinical trials in Germany", Control Clin Trials, 12(4 Suppl), pp.91S~105S (1991)
- Thase ME, "Remission rates during treatment with venlafaxine or selective serotonin reuptake inhibitors", Br J Psychiatry, 178, pp.234~241 (2001)
- Lieberman JA, "Comparing the effects of antidepressants: consensus guidelines for evaluating quantitative reviews of antidepressant efficacy", Neuropsychopharmacology, 30, pp.445~460 (2005)
- Yang H, "Is there a placebo problem in antidepressant trials?", Curr Top Med Chem, 5, pp.1077~1086 (2005)
- Mundt JC, "Is it easier to find what you are looking for if you think you know what it looks like?", J Clin Psychopharmacol, 27, pp.121~125 (2007)
- Kemp AS, "What is causing the reduced drug-placebo difference in recent schizophrenia clinical trials and what can be done about it?", Schizophr Bull, 36, pp.504~509 (2010)
- Depp C, "Clinical trials: bridging the gap between efficacy and effectiveness", Int Rev Psychiatry, 19, pp.531~539 (2007)
- Zerhouni EA, "Clinical research at a crossroads: the NIH roadmap", J Investig Med, 54, pp.171~173 (2006)
- Lieberman JA, "Effectiveness of antipsychotic drugs in patients with chronic schizophrenia", N Engl J Med, 353, pp.1209~1223 (2005)
- Sachs GS, "Rationale, design, and methods of the systematic treatment enhancement program for bipolar disorder (STEP-BD)", Biol Psychiatry, 53, pp.1028~1042 (2003)
- Fava M, "Background and rationale for the sequenced treatment alternatives to relieve depression (STAR*D) study", Psychiatr Clin North Am, 26, pp.457~494 (2003)
- Davies LM, "Cost-effectiveness of first- v. second-generation antipsychotic drugs: results from a randomised controlled trial in schizophrenia responding poorly to previous therapy", Br J Psychiatry, 191, pp.14~22 (2007)
- Timmermans S, "The promises and pitfalls of evidencebased medicine", Health Aff (Millwood), 24, pp.18~28 (2005)
- "EBM: Levels of Evidence. Essential Evidence Plus"[URL]